Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Observer-Blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of a MF59-Adjuvanted Quadrivalent Subunit Cell-derived Influenza Vaccine (aQIVc) in Comparison With Quadrivalent Influenza Vaccines, in Adults Aged 50 Years and Older.
Conditions
Interventions
Investigational aQIVc
licensed QIVr
+1 more
Locations
96
United States
Alliance for Multispecialty Research (AMR) Phoenix
Tempe, Arizona, United States
Baptist Health Center for Clinical Research
Little Rock, Arkansas, United States
Marvel Clinical Research
Huntington Beach, California, United States
Paradigm Clinical Research Center, LLC
Redding, California, United States
Clinical Research Consulting, Inc.
Milford, Connecticut, United States
Chase Medical Research, LLC
Waterbury, Connecticut, United States
Start Date
November 3, 2023
Primary Completion Date
March 5, 2024
Completion Date
January 30, 2025
Last Updated
April 27, 2025
NCT06355232
NCT06622590
NCT05227001
NCT05446740
NCT06602531
NCT05823974
Lead Sponsor
Seqirus
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions